Adjuvante endokrine Therapie des Mammakarzinoms

• Literatur

• 1 Arbeitsgemeinschaft Gynäkologische Onkologie e.V. Kommission Mamma. Empfehlungen Gynäkologische Onkologie. Februar 2010 http://www.ago-online.org/index.php?.site=mamma_guide&lang=de
• 2 Bliss JM. et al. 32^th. Annual San Antonio Breast Cancer Symposium. 2009 Oral Presentation #12.
• 3 Hershman DL. et al. Effect of early discontinuation and nonadherence to adjuvant hormone therapy on mortality in women with breast cancer. 2010 ASCO Annual Meeting. J Clin Oncol 2010; 28 Suppl.; Abstr 578 15s.
• 4 Dent SF. et al. Breast Cancer Res Treat. 2007 106 (Suppl. 1; Abstr. 2079).
• 5 Hadji P. et al. Ann Oncol 2009; 20: 1203-1209.
• 6 Hadji P. et al. Breast 2009; 18: 159-164.
• 7 Coleman R. et al. 31^st. Annual San Antonio Breast Cancer Symposium. 2008 Abstract 1128.
• 8 Ortmann O. et al. Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor?. Recommendations of an expert panel. Cancer Treatment Reviews. Published online 1. July 2010.